Champions Oncology | 8-K: FY2026 Q1 Revenue: USD 14 M

Revenue: As of FY2026 Q1, the actual value is USD 14 M.

EPS: As of FY2026 Q1, the actual value is USD -0.03.

EBIT: As of FY2026 Q1, the actual value is USD -452 K.

Segment Revenue

• Total revenue for the first quarter of fiscal 2026 was $14.0 million, a slight decrease from $14.1 million in the same period last year, with a $400,000 decline in service revenue and a $300,000 increase in data license revenue.

Operational Metrics

• Loss from operations was - $527,000, compared to an income from operations of $1.3 million in the first quarter of fiscal 2025.
• Gross margin for the quarter was 43%, down from 50% in the prior year.
• Total costs and operating expenses increased by $1.8 million or 14.1%, from $12.7 million in the first quarter of fiscal 2025 to $14.5 million in the first quarter of fiscal 2026.

Cash Flow

• Net cash provided by operating activities was approximately $600,000 for the quarter.
• Net cash used in investing activities was approximately $46,000.
• Net cash used in financing activities was $14,000.

Unique Metrics

• Adjusted EBITDA was $60,000, a significant decrease from $2.0 million in the first quarter of fiscal 2025.

Outlook / Guidance

• Champions Oncology anticipates continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for proprietary data offerings.